KR102882178B1 - 신규한 디펩티드 화합물과 이의 용도 - Google Patents

신규한 디펩티드 화합물과 이의 용도

Info

Publication number
KR102882178B1
KR102882178B1 KR1020217016217A KR20217016217A KR102882178B1 KR 102882178 B1 KR102882178 B1 KR 102882178B1 KR 1020217016217 A KR1020217016217 A KR 1020217016217A KR 20217016217 A KR20217016217 A KR 20217016217A KR 102882178 B1 KR102882178 B1 KR 102882178B1
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217016217A
Other languages
English (en)
Korean (ko)
Other versions
KR20210086682A (ko
Inventor
민 리
유 후앙
Original Assignee
화하이 유에스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화하이 유에스 인코퍼레이티드 filed Critical 화하이 유에스 인코퍼레이티드
Publication of KR20210086682A publication Critical patent/KR20210086682A/ko
Application granted granted Critical
Publication of KR102882178B1 publication Critical patent/KR102882178B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020217016217A 2018-10-29 2019-10-25 신규한 디펩티드 화합물과 이의 용도 Active KR102882178B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751984P 2018-10-29 2018-10-29
US62/751,984 2018-10-29
PCT/US2019/057985 WO2020092139A1 (en) 2018-10-29 2019-10-25 Novel dipeptide compounds and uses thereof

Publications (2)

Publication Number Publication Date
KR20210086682A KR20210086682A (ko) 2021-07-08
KR102882178B1 true KR102882178B1 (ko) 2025-11-05

Family

ID=70464360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217016217A Active KR102882178B1 (ko) 2018-10-29 2019-10-25 신규한 디펩티드 화합물과 이의 용도

Country Status (10)

Country Link
US (1) US12209141B2 (OSRAM)
EP (1) EP3873916B8 (OSRAM)
JP (1) JP7503561B2 (OSRAM)
KR (1) KR102882178B1 (OSRAM)
CN (2) CN116813691B (OSRAM)
AU (1) AU2019371209B2 (OSRAM)
CA (1) CA3117599A1 (OSRAM)
IL (1) IL282676B1 (OSRAM)
TW (1) TWI870362B (OSRAM)
WO (1) WO2020092139A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116813691B (zh) * 2018-10-29 2024-04-12 丽珠医药集团股份有限公司 新的二肽类化合物及其用途
JP2026504578A (ja) * 2023-02-16 2026-02-05 浙江華海薬業股▲フン▼有限公司 ジペプチド類化合物の塩、ならびにその調製方法および使用
CN118496301A (zh) * 2023-02-16 2024-08-16 丽珠医药集团股份有限公司 一种二肽类化合物的盐、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
MX9201416A (es) * 1991-03-28 1992-10-01 Rhone Poulenc Rorer Int Peptidos y pseudopeptidos antitromboticos.
JP4561696B2 (ja) 1994-01-27 2010-10-13 三菱化学株式会社 プロリンアミド誘導体
FR2793248B1 (fr) * 1999-05-03 2001-06-29 Adir Nouveaux derives de 2,3-methano-aminoacides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6774110B2 (en) 2001-03-19 2004-08-10 Lg Life Sciences Ltd. Orally available peptidic thrombin inhibitors
FR2836143B1 (fr) 2002-02-21 2004-04-16 Servier Lab Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP1778616A1 (en) * 2004-08-09 2007-05-02 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
DE102004062864A1 (de) 2004-12-21 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Folienbehälter
CN100502914C (zh) * 2005-10-24 2009-06-24 丽珠医药集团股份有限公司 一种治疗脑中风的中药组合物及其制备方法
KR20080104352A (ko) * 2006-03-29 2008-12-02 쉐링 코포레이션 트롬빈 수용체 길항제로서 유용한 모노사이클릭 및 비사이클릭 힘바신 유도체
EP2152664B1 (en) * 2007-06-13 2014-09-03 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
CN102464701B (zh) * 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
CN102796168B (zh) * 2011-05-27 2014-02-26 首都医科大学 一种具有溶血栓活性的化合物，及其制备方法和应用
CN103833827B (zh) * 2012-11-27 2016-08-03 上海医药工业研究院 一种酰胺类化合物、其药物组合物、制备方法及应用
JP6386035B2 (ja) * 2013-06-12 2018-09-05 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 金属酵素阻害剤化合物
CN106316975A (zh) * 2015-06-15 2017-01-11 山东轩竹医药科技有限公司 酰胺类化合物及其作为tgr5激动剂的应用
CN116813691B (zh) * 2018-10-29 2024-04-12 丽珠医药集团股份有限公司 新的二肽类化合物及其用途

Also Published As

Publication number Publication date
CN113195515B (zh) 2024-11-15
AU2019371209A1 (en) 2021-05-27
CA3117599A1 (en) 2020-05-07
JP7503561B2 (ja) 2024-06-20
TW202031674A (zh) 2020-09-01
EP3873916B8 (en) 2025-03-26
US20210395299A1 (en) 2021-12-23
CN116813691B (zh) 2024-04-12
WO2020092139A1 (en) 2020-05-07
EP3873916A1 (en) 2021-09-08
EP3873916B1 (en) 2025-02-19
TWI870362B (zh) 2025-01-21
EP3873916C0 (en) 2025-02-19
US12209141B2 (en) 2025-01-28
JP2022509366A (ja) 2022-01-20
EP3873916A4 (en) 2022-08-10
IL282676A (en) 2021-06-30
AU2019371209B2 (en) 2025-05-01
IL282676B1 (en) 2026-03-01
CN116813691A (zh) 2023-09-29
KR20210086682A (ko) 2021-07-08
CN113195515A (zh) 2021-07-30

Similar Documents

Publication Publication Date Title
DE69931393T2 (de) Antithrombotische amide
JP6154473B2 (ja) 第ＸＩａ因子阻害剤の結晶形
EP2611779B1 (en) CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR
EP3873916B1 (en) Novel dipeptide compounds and uses thereof
JP2013543850A (ja) 新規な化合物、その製造方法および用途
DE60114640T2 (de) Antithrombosemittel
CN101421242B (zh) 二酰胺衍生物
RU2731618C2 (ru) Нестероидные модуляторы глюкокортиодидных рецепторов для местной доставки лекарств
HK40060683A (en) Novel dipeptide compounds and uses thereof
HK40060683B (en) Novel dipeptide compounds and uses thereof
US20250179118A1 (en) Novel dipeptide compounds and uses thereof
HK40094572A (zh) 新的二肽类化合物及其用途
HK40094572B (zh) 新的二肽类化合物及其用途
KR102670554B1 (ko) 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
JP2002526531A (ja) トロンビン阻害剤としてのベンズアミド誘導体
KR100377558B1 (ko) 피페리딘 작용기를 갖는 선택적 트롬빈 억제제
JP2011073993A (ja) 抗凝固作用を有するキノキサリンカルボキサミド誘導体
HK1212333B (en) Crystalline forms of a factor xia inhibitor
HK1186181B (en) Crystalline forms of a factor xa inhibitor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)